Prodrug for tumor therapy
Scientists of the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-Molar range) as well as a selective tumor therapy through their prodrugs based on the Antibody Directed Enzyme Prodrug Therapy (ADEPT). Selective is achieved by the specific tumor targeting through the antibody. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site through the enzyme, which is coupled to the antibody. While prodrugs have a low cytotoxicity, active drugs show an unbelievable cytotoxicity in the pico-molar range, much higher than actually used Doxorubicin. The drugs could be used equivalent to current chemotherapeutic agents or combined with e.g. a targeting-antibody.
We are now looking for companies, which are interested in licensing, developing and commercializing our approach.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-152
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…
